BMS brings in Novartis exec to round out post Celgene acquisition team

With the hire of Novartis’ Samit Hirawat, Bristol-Myers gains some of the R&D chops it needs to become less reliant on its blockbuster checkpoint inhibitors.

As it nears the close of its acquisition of Celgene Corp. (NASDAQ:CELG), Bristol-Myers Squibb Co. (NYSE:BMY) announced Wednesday that its post-acquisition

Read the full 459 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE